{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:22:24Z","timestamp":1793881344220,"version":"4.7.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Understanding the immune responses elicited by SARS-CoV-2 infection is critical in terms of protection against reinfection and, thus, for public health policy and vaccine development for COVID-19. In this study, using either live SARS-CoV-2 particles or retroviruses pseudotyped with the SARS-CoV-2 S viral surface protein (Spike), we studied the neutralizing antibody (nAb) response in serum samples from a cohort of 140 SARS-CoV-2 qPCR-confirmed infections, including patients with mild symptoms and also more severe forms, including those that required intensive care. We show that nAb titers correlated strongly with disease severity and with anti-spike IgG levels. Indeed, patients from intensive care units exhibited high nAb titers; conversely, patients with milder disease symptoms had heterogeneous nAb titers, and asymptomatic or exclusive outpatient-care patients had no or low nAbs. We found that nAb activity in SARS-CoV-2-infected patients displayed a relatively rapid decline after recovery compared to individuals infected with other coronaviruses. Moreover, we found an absence of cross-neutralization between endemic coronaviruses and SARS-CoV-2, indicating that previous infection by human coronaviruses may not generate protective nAbs against SARS-CoV-2. Finally, we found that the D614G mutation in the spike protein, which has recently been identified as the current major variant in Europe, does not allow neutralization escape. Altogether, our results contribute to our understanding of the immune correlates of SARS-CoV-2-induced disease, and rapid evaluation of the role of the humoral response in the pathogenesis of SARS-CoV-2 is warranted.<\/jats:p>","DOI":"10.1038\/s41423-020-00588-2","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T09:08:40Z","timestamp":1609924120000},"page":"318-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":303,"title":["A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity"],"prefix":"10.1038","volume":"18","author":[{"given":"Vincent","family":"Legros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Denolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Vogrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Boson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eglantine","family":"Siret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josselin","family":"Rigaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Pillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Grattard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Gonzalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omran","family":"Allatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Berthelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"P\u00e9lissier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Thiery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Botelho-Nevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Walzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8842-3726","authenticated-orcid":false,"given":"Fran\u00e7ois-Lo\u00efc","family":"Cosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bourlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pozzetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"588_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/joim.13091","volume":"288","author":"G Pascarella","year":"2020","unstructured":"Pascarella, G. et al. COVID-19 diagnosis and management: a comprehensive review. J. Intern. Med. 288, 192\u2013206 (2020).","journal-title":"J. Intern. Med."},{"key":"588_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11481-020-09924-9","volume":"15","author":"A Acharya","year":"2020","unstructured":"Acharya, A., Kevadiya, B. D., Gendelman, H. E. & Byrareddy, S. N. SARS-CoV-2 infection leads to neurological dysfunction. J. Neuroimmune Pharm. 15, 167\u201373. (2020).","journal-title":"J. Neuroimmune Pharm."},{"key":"588_CR3","unstructured":"Bryant, J. E., et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Sci. Immunol. 5, eabc6347 (2020)."},{"key":"588_CR4","unstructured":"Suthar, M. S., et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Reports Med. 1, https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2666379120300525?via%3Dihub (2020)."},{"key":"588_CR5","unstructured":"Xiang, F. et al. Antibody detection and dynamic characteristics in patients with COVID-19. Clin. Infect. Dis. ciaa461 (2020)."},{"key":"588_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/cid\/ciaa310","volume":"71","author":"L Guo","year":"2020","unstructured":"Guo, L. et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin. Infect. Dis. 71, 778\u2013785 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"588_CR7","unstructured":"Zhao, R. et al. Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection. Clin. Infect. Dis. ciaa523 (2020)."},{"key":"588_CR8","doi-asserted-by":"publisher","unstructured":"Wu, F. et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Preprint at https:\/\/doi.org\/10.1101\/2020.03.30.20047365 (2020).","DOI":"10.1101\/2020.03.30.20047365"},{"key":"588_CR9","doi-asserted-by":"publisher","unstructured":"Long, Q. -X. et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. Preprint at https:\/\/doi.org\/10.1101\/2020.03.18.20038018 (2020).","DOI":"10.1101\/2020.03.18.20038018"},{"key":"588_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1017\/S0950268800048019","volume":"105","author":"KA Callow","year":"1990","unstructured":"Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435\u2013446 (1990).","journal-title":"Epidemiol. Infect."},{"key":"588_CR11","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3201\/eid2210.160706","volume":"22","author":"DC Payne","year":"2016","unstructured":"Payne, D. C. et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerg. Infect. Dis. 22, 1824\u20131826 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"588_CR12","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1056\/NEJMc070348","volume":"357","author":"WC Cao","year":"2007","unstructured":"Cao, W. C., Liu, W., Zhang, P. H., Zhang, F. & Richardus, J. H. Disappearance of antibodies to SARS-associated coronavirus after recovery. N. Engl. J. Med. 357, 1162\u20131163 (2007).","journal-title":"N. Engl. J. Med."},{"key":"588_CR13","doi-asserted-by":"crossref","unstructured":"Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182, 812\u2013827.e19 (2020).","DOI":"10.1016\/j.cell.2020.06.043"},{"key":"588_CR14","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1128\/JVI.80.3.1302-1310.2006","volume":"80","author":"R Broer","year":"2006","unstructured":"Broer, R., Boson, B., Spaan, W., Cosset, F. L. & Corver, J. Important role for the transmembrane domain of severe acute respiratory syndrome coronavirus spike protein during entry. J. Virol. 80, 1302\u20131310 (2006).","journal-title":"J. Virol."},{"key":"588_CR15","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.1128\/JVI.79.10.6023-6034.2005","volume":"79","author":"D Lavillette","year":"2005","unstructured":"Lavillette, D. et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 79, 6023\u20136034 (2005).","journal-title":"J. Virol."},{"key":"588_CR16","doi-asserted-by":"publisher","first-page":"104357","DOI":"10.1016\/j.jcv.2020.104357","volume":"127","author":"JA Siordia Jr","year":"2020","unstructured":"Siordia, J. A. Jr Epidemiology and clinical features of COVID-19: a review of current literature. J. Clin. Virol. 127, 104357 (2020).","journal-title":"J. Clin. Virol."},{"key":"588_CR17","doi-asserted-by":"publisher","unstructured":"Kumar, A. et al. Clinical features of COVID-19 and factors associated with severe clinical course: a systematic review and meta-analysis. Preprint at https:\/\/doi.org\/10.2139\/ssrn.3566166 (2020).","DOI":"10.2139\/ssrn.3566166"},{"key":"588_CR18","unstructured":"Guan, W. J. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J. 55, 2000547 (2020)."},{"key":"588_CR19","doi-asserted-by":"publisher","first-page":"117836","DOI":"10.1016\/j.lfs.2020.117836","volume":"255","author":"PB Tong","year":"2020","unstructured":"Tong, P. B., Lin, L. Y. & Tran, T. H. Coronaviruses pandemics: can neutralizing antibodies help? Life Sci. 255, 117836 (2020).","journal-title":"Life Sci."},{"key":"588_CR20","doi-asserted-by":"crossref","unstructured":"Li, Q. et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284\u20131294.e9 (2020).","DOI":"10.1016\/j.cell.2020.07.012"},{"key":"588_CR21","doi-asserted-by":"crossref","unstructured":"Fafi-Kremer, S. et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine 59, 102915 (2020).","DOI":"10.1016\/j.ebiom.2020.102915"},{"key":"588_CR22","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. ciaa344 (2020)."},{"key":"588_CR23","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients. Clin. Infect. Dis. ciaa721 (2020).","DOI":"10.1101\/2020.04.15.20065623"},{"key":"588_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.virol.2020.09.008","volume":"551","author":"L Li","year":"2020","unstructured":"Li, L. et al. Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients. Virology 551, 26\u201335 (2020).","journal-title":"Virology"},{"key":"588_CR25","unstructured":"Ko, J. H. et al. Neutralizing antibody production in asymptomatic and mild COVID-19 patients, in comparison with pneumonic COVID-19 patients. J. Clin. Med. 9, 2268 (2020)."},{"key":"588_CR26","unstructured":"Altmann, D. M. & Boyton, R. J. SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection. Sci. Immunol. 5, eabd6160 (2020)."},{"key":"588_CR27","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054\u20131062 (2020).","journal-title":"Lancet"},{"key":"588_CR28","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1001\/jamainternmed.2020.4616","volume":"180","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern. Med. 180, 1356\u20131362 (2020).","journal-title":"JAMA Intern. Med."},{"key":"588_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","volume":"22","author":"JA Tetro","year":"2020","unstructured":"Tetro, J. A. Is COVID-19 receiving ADE from other coronaviruses? Microbes. Infect. 22, 72\u201373 (2020).","journal-title":"Microbes. Infect."},{"key":"588_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","volume":"584","author":"AM Arvin","year":"2020","unstructured":"Arvin, A. M. et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature 584, 353\u2013363 (2020).","journal-title":"Nature"},{"key":"588_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02893-8","volume":"24","author":"X Yu","year":"2020","unstructured":"Yu, X. et al. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression. Crit. Care 24, 170 (2020).","journal-title":"Crit. Care"},{"key":"588_CR32","unstructured":"Amodio, E. et al. SARS-CoV-2 Viral load, IFNlambda polymorphisms and the course of COVID-19: an observational study. J. Clin. Med. 9, 3315 (2020)."},{"key":"588_CR33","unstructured":"Weissleder, R., Lee, H., Ko, J. & Pittet, M. J. COVID-19 diagnostics in context. Sci. Transl. Med. 12, eabc1931 (2020)."},{"key":"588_CR34","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1515\/cclm-2020-0285","volume":"58","author":"G Lippi","year":"2020","unstructured":"Lippi, G., Simundic, A. M. & Plebani, M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin. Chem. Lab. Med. 58, 1070\u20131076 (2020).","journal-title":"Clin. Chem. Lab. Med."},{"key":"588_CR35","doi-asserted-by":"crossref","unstructured":"Wang, K. et al. Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection. Clin. Infect. Dis. ciaa1143 (2020).","DOI":"10.1101\/2020.07.14.20151159"},{"key":"588_CR36","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","volume":"9","author":"H Han","year":"2020","unstructured":"Han, H. et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg. Microbes Infect. 9, 1123\u20131130 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"588_CR37","doi-asserted-by":"publisher","first-page":"e01136","DOI":"10.1002\/cti2.1136","volume":"9","author":"H Hou","year":"2020","unstructured":"Hou, H. et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin. Transl. Immunol. 9, e01136 (2020).","journal-title":"Clin. Transl. Immunol."},{"key":"588_CR38","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00134-020-06157-5","volume":"46","author":"S Fourati","year":"2020","unstructured":"Fourati, S., Hue, S., Pawlotsky, J. M., Mekontso-Dessap, A. & de Prost, N. SARS-CoV-2 viral loads and serum IgA\/IgG immune responses in critically ill COVID-19 patients. Intensive Care Med. 46, 1781\u20131783 (2020).","journal-title":"Intensive Care Med."},{"key":"588_CR39","unstructured":"Gudbjartsson, D. F. et al. Humoral immune response to SARS-CoV-2 in Iceland. N. Engl. J. Med. 393, 1724\u20131734 (2020)."},{"key":"588_CR40","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200\u20131204 (2020).","journal-title":"Nat. Med."},{"key":"588_CR41","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1172\/JCI138759","volume":"130","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J. Clin. Invest. 130, 5235\u20135244 (2020).","journal-title":"J. Clin. Invest."},{"key":"588_CR42","doi-asserted-by":"crossref","unstructured":"Ren, L. et al. Antibody responses and clinical outcomes in adults hospitalized with severe COVID-19: a post hoc analysis of LOTUS China Trial. Clin. Infect. Dis. ciaa1247 (2020).","DOI":"10.1093\/cid\/ciaa1247"},{"key":"588_CR43","doi-asserted-by":"crossref","unstructured":"McAndrews, K. M. et al. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity. JCI Insight 5, e142386 (2020).","DOI":"10.1172\/jci.insight.142386"},{"key":"588_CR44","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","volume":"105","author":"MA Tortorici","year":"2019","unstructured":"Tortorici, M. A. & Veesler, D. Structural insights into coronavirus entry. Adv. Virus Res. 105, 93\u2013116 (2019).","journal-title":"Adv. Virus Res."},{"key":"588_CR45","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1126\/science.abc4776","volume":"369","author":"A Chandrashekar","year":"2020","unstructured":"Chandrashekar, A. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369, 812\u2013817 (2020).","journal-title":"Science"},{"key":"588_CR46","unstructured":"Seow, J. et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. Nat Microbiol. https:\/\/www.nature.com\/articles\/s41564-020-00813-8 (2020)."},{"key":"588_CR47","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1056\/NEJMc2025179","volume":"383","author":"FJ Ibarrondo","year":"2020","unstructured":"Ibarrondo, F. J. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N. Engl. J. Med. 383, 1085\u20131087 (2020).","journal-title":"N. Engl. J. Med."},{"key":"588_CR48","unstructured":"Isho, B. et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci. Immunol. 5, eabe5511 (2020)."},{"key":"588_CR49","unstructured":"Iyer, A. S. et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci. Immunol. 5, eabe0367 (2020)."},{"key":"588_CR50","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"588_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1440-1843.2006.00783.x","volume":"11","author":"H Mo","year":"2006","unstructured":"Mo, H. et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology 11, 49\u201353 (2006).","journal-title":"Respirology"},{"key":"588_CR52","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1086\/423286","volume":"190","author":"Y Nie","year":"2004","unstructured":"Nie, Y. et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J. Infect. Dis. 190, 1119\u20131126 (2004).","journal-title":"J. Infect. Dis."},{"key":"588_CR53","unstructured":"Liu, D. X., Liang, J. Q. & Fung, T. S. in Reference Module in Life Sciences (Elsevier, 2020)."},{"key":"588_CR54","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41577-020-0389-z","volume":"20","author":"A Sette","year":"2020","unstructured":"Sette, A. & Crotty, S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat. Rev. Immunol. 20, 457\u2013458 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"588_CR55","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u2013501e15 (2020).","journal-title":"Cell"},{"key":"588_CR56","doi-asserted-by":"crossref","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"588_CR57","doi-asserted-by":"publisher","first-page":"102890","DOI":"10.1016\/j.ebiom.2020.102890","volume":"58","author":"R Yang","year":"2020","unstructured":"Yang, R. et al. Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine 58, 102890 (2020).","journal-title":"EBioMedicine"},{"key":"588_CR58","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","volume":"26","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033\u20131036 (2020).","journal-title":"Nat. Med."}],"container-title":["Cellular &amp; Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-00588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-00588-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41423-020-00588-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:23:00Z","timestamp":1684603380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41423-020-00588-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1038\/s41423-020-00588-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.08.27.20182493","asserted-by":"object"}]},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"9 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}